---
title: "Serina Therapeutics Faces NYSE Delisting Risk Over Shareholders' Equity Deficiency"
description: "Serina Therapeutics Inc. faces delisting risk from the NYSE due to a deficiency in stockholders' equity, which dropped to $1.6 million as of September 30, 2025. The company has reported losses in thre"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/272745731.md"
published_at: "2026-01-15T21:03:59.000Z"
---

# Serina Therapeutics Faces NYSE Delisting Risk Over Shareholders' Equity Deficiency

> Serina Therapeutics Inc. faces delisting risk from the NYSE due to a deficiency in stockholders' equity, which dropped to $1.6 million as of September 30, 2025. The company has reported losses in three of its last four fiscal years, failing to meet the NYSE's continued listing criteria. Serina must submit a compliance plan by February 8, 2026, to regain compliance by July 9, 2027, or face potential delisting proceedings.

Serina Therapeutics Inc. has received a deficiency notification from the New York Stock Exchange (NYSE) regarding its stockholders’ equity, which fell to $1.6 million as of September 30, 2025. The company has also reported losses in three of its four most recent fiscal years, putting it below the continued listing criteria under Sections 1003(a)(i) and (ii) of the NYSE American Company Guide. Serina must submit a compliance plan by February 8, 2026, outlining actions to regain compliance by July 9, 2027. Failure to submit an acceptable plan may result in delisting proceedings. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001708599-26-000003), on January 15, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [SER.US - Serina Therapeutics](https://longbridge.com/en/quote/SER.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 首席科学官 Randall Moreadith 报告出售 Serina Therapeutics Inc.的普通股 | Serina Therapeutics Inc. 的首席科学官 Randall Moreadith 报告了该公司普通股的出售。完整的文件可通过提供的链接获取。此新闻简报由 Public Technologies 生成，仅供信息参考，不应被视 | [Link](https://longbridge.com/en/news/272107151.md) |
| Serina Therapeutics 的首席科学官 Randall Moreadith 报告了普通股的出售 | Randall Moreadith，Serina Therapeutics Inc. 的首席科学官，报告了该公司普通股的出售。完整的文件可通过提供的链接获取。此新闻简报由公共技术生成，仅供信息参考，不应被视为财务、投资或法律建议。Serin | [Link](https://longbridge.com/en/news/274692579.md) |
| “AI 交易” 的关键变量：服务业敞口越高，AI 颠覆风险越大，“AI 基建” 最有利 | 大摩量化研究显示，“服务业敞口” 是 AI 投资的关键变量，与收益呈显著负相关。由于市场担忧 AI 颠覆，服务业敞口高达 53% 的 “AI 采用者” 表现垫底。相反，“AI 基础设施” 敞口仅 14%，受颠覆风险最小且受益于资本支出，在六 | [Link](https://longbridge.com/en/news/275977957.md) |
| 期权交易中最容易被忽视的风险：资本漂移 | 期权交易中最被忽视的风险：资本漂移 | [Link](https://longbridge.com/en/news/275985877.md) |
| 期权热点｜上周五 NBIS 大涨 9%，部分看涨期权飙升 378% | 美东时间 02 月 13 日，Nebius 期权总成交 179098 张，看涨期权占比 71%，看跌期权占比 28%。 | [Link](https://longbridge.com/en/news/276030151.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.